Scott Platshon

EcoR1 Capital LLC (EcoR1) is an independent registered investment advisor and hedge fund manager headquartered in San Francisco, California. The firm was founded by Oleg Nodelman in 2012. EcoR1 serves as the general partner of and investment adviser to investment funds and provides investment advice to separate account clients.

Panacea Acquisition Corp. is a blank check company with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in April 2020 and is headquartered in San Francisco, CA.

Silverback Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. The company was founded by Peter A. Thompson January 4, 2016 and is headquartered in Seattle, WA.

Panacea Acquisition Corp. II operates as a blank check company. It seeks to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 14, 2021 and is headquartered in San Francisco, CA.

Ajax Therapeutics, Inc. operates as a biomedical company. The company is headquartered in New York, NY.

Kumquat Biosciences, Inc. provides biotechnology services. The company was founded by Yi Liu and Pingda Ren and is headquartered in San Diego, CA.

Terremoto Biosciences, Inc. is a drug discovery and development company that creates highly targeted, small molecule medicines with unmatched selectivity, potency, and efficacy to deliver superior therapeutic benefit to patients. The company is based in San Francisco, CA. Terremoto is supported by leading investors, including OrbiMed, Third Rock Ventures, EcoR1 Capital, Novo Holdings, and Cormorant Capital. The company aims to expand the universe of drug targets and improve existing medicines by unleashing the power of covalent chemistry. Terremoto was founded by Peter A. Thompson and Matthew P. Jacobson, and Peter A. Thompson has been the CEO since incorporation.